Boston Scientific Corporation vs VanEck Australian Floating Rate ETF — how do they compare? Boston Scientific Corporation trades at $42.62 (market cap $66.37B), while VanEck Australian Floating Rate ETF trades at $50.97. The key difference: VanEck Australian Floating Rate ETF is trading nearer its 52-week high, Boston Scientific Corporation nearer its low. Which is the better fit depends on your goals.
| BSX | FLOT | |
|---|---|---|
Market Cap | $66.37B | — |
Sector | Health | Sector/Thematic |
52-Week High | $108.14 | $51.09 |
52-Week Low | $42.63 | $50.72 |
Enterprise Value | $75.94B | — |
Signals from Pluang's Aura AI — not financial advice
Boston Scientific (BSX) trades at $44.65, down 0.27% with bearish technical signals despite strong fundamentals. The company delivered three consecutive earnings beats with Q3-Q1 2026 EPS exceeding expectations, while revenue grew to $20.07B in 2025 with improving profit margins. Technical indicators show bearish momentum with support at $44 and resistance at $45, though Wall Street maintains 88% buy rating with $70.20 consensus target.
BSX presents a compelling value opportunity with attractive valuation multiples (P/E 18.68, P/S 3.24) and robust financial health, though near-term headwinds include competitive pressures in key segments and recent stock price decline of nearly 60% from 2025 highs. The strong analyst consensus suggests significant upside potential if execution improves.
FLOT trades at $50.98 with no recent price change. Technical indicators show a bullish moving average signal but bearish oscillators, with the 6-day RSI at 88.89 indicating overbought conditions. Recent dividends of $0.17 and $0.18 per share reflect income distribution. The ETF focuses on high-quality floating rate bonds, offering a 4.0% SEC yield, with potential upside if the Federal Reserve raises rates.
The outlook for FLOT is tied to interest rate movements, with potential gains from rising yields but risks from inflation and geopolitical tensions. Investors seeking short-term income may find value, though overbought technicals suggest caution. Credit quality remains high, but macroeconomic shifts could impact performance.
Trailing returns across standard periods
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, structural heart disease, upper gastrointestinal tract diagnostics, interventional oncology, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.
Read more on BSX →FLOT provides exposure to a diversified portfolio of Australian dollar-denominated floating rate notes. It tracks the Bloomberg AusBond Credit FRN 0+ Yr Index, focusing on high-quality, investment-grade bonds from top Australian banks and financial institutions.
Read more on FLOT →